Xeris Biopharma Holdings, Inc. (0A8E)
LSE 
Summary
0A8E Chart
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (0A8E) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xeris Biopharma Holdings, Inc. ever had a stock split?
Xeris Biopharma Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Shannon CEO | LSE Exchange | 98422E103 CUSIP |
| US Country | 435 Employees | - Last Dividend | - Last Split | 21 Jun 2018 IPO Date |
Overview
Xeris Biopharma Holdings, Inc. is an innovative biopharmaceutical company based in Chicago, Illinois, with a strong commitment to enhancing patient care by developing and commercializing unique therapies. Founded in 2005, Xeris Biopharma has embarked on a mission to address unmet medical needs through its diverse portfolio of products. The company particularly focuses on leveraging its proprietary non-aqueous XeriSol and XeriJect formulations technologies to create and deliver better pharmacological solutions. These technologies are designed to enable stable, ready-to-use, injectable and infusible drug formulations that can improve patient compliance, convenience, and efficacy across a wide range of therapeutic areas. Xeris Biopharma’s forward-looking approach emphasizes the development of treatments that cater to pediatric and adult patients alike, with its products receiving approval for significant medical conditions such as severe hypoglycemia, primary periodic paralysis, Cushing's syndrome, and hypothyroidism.
Products and Services
- Gvoke
- Keveyis
- Recorlev
- XP-8121
- XeriSol and XeriJect Technologies
A revolutionary ready-to-use, liquid stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients. Gvoke represents a significant advancement in the emergency management of diabetic patients who experience severe hypoglycemia, offering ease of use and rapid effectiveness.
Keveyis addresses the needs of patients suffering from hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. As the first and only FDA-approved treatment for these conditions, Keveyis significantly improves the quality of life for individuals affected by these rare disorders.
This cortisol synthesis inhibitor is specifically aimed at treating adult patients with Cushing's syndrome, a condition characterized by excessive levels of the hormone cortisol. Recorlev has been proven to reduce cortisol levels, mitigating the symptoms and complications associated with this disorder.
Currently under development, XP-8121 is a promising once-weekly subcutaneous injection of levothyroxine intended for the treatment of hypothyroidism. Being in phase I clinical trial, XP-8121 aims to improve the standard of care by offering a more convenient dosing regimen compared to daily oral levothyroxine therapies.
Xeris Biopharma's proprietary non-aqueous formulation technologies, XeriSol and XeriJect, enable the development of stable, ready-to-use, injectable and infusible drug formulations. These platforms are instrumental in creating improved versions of existing therapies, potentially enhancing patient compliance, convenience, and efficacy.
